Chordia Therapeutics (190A): H1 Earnings for the Year Ending August 2026 — Operating Loss of 662 Million Yen

Chordia Therapeutics (190A) has released its financial results for the first half of the fiscal year ending August 2026, reporting an operating loss of 662 million yen, an ordinary loss of 632 million yen, and a net loss of 633 million yen. Basic earnings per share (EPS) stood at -8.95 yen.

From a balance sheet perspective, the company maintains a robust equity ratio of 91.8%, reflecting a strong financial foundation. Meanwhile, retained earnings were recorded at -0.63 billion yen, and cash and cash equivalents stood at 2.45 billion yen. As a drug-discovery biotech venture continuing its R&D investments, the market will likely focus on its future business progress and path toward profitability supported by its solid capital base and liquidity.

---

Correction (September 19, 2026)：We clarified that this article covers the first half of the fiscal year ending August 2026 and corrected the source link to the report supporting its figures. Source disclosure